An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

November 2, 2022

Study Completion Date

November 2, 2022

Conditions
Kidney DiseasesGlomerulosclerosisFocal Segmental NephrosisLipoid Urologic DiseaseGlomerulonephritisNephritisNephrosis
Interventions
DRUG

GFB-887

GFB-887 is a potent, small molecule inhibitor of TRPC5.

Trial Locations (17)

10029

Icahn School of Medicine at Mount Sinai, New York

43210

The Ohio State University Wexner Medical Center, Columbus

48066

St. Clair Nephrology, Roseville

60521

NANI Research, LLC, Hinsdale

64111

Clinical Research Consultants, Kansas City

77054

Prolato Clinical Research Center, Houston

77598

Tranquility Research, Webster

78212

Clinical Advancement Center, PLLC, San Antonio

80045

University of Colorado Anschutz Medical Center, Aurora

80230

Colorado Kidney Care (Denver Nephrology), Denver

83687

Boise Kidney and Hypertension Institute, Nampa

84115

Utah Kidney Center, Salt Lake City

90022

Academic Medical Research Institute (AMRI), Los Angeles

91324

Amicis Research Center, Northridge

92395

Kidney and Hypertension Center - Apple Valley, Victorville

99204

Providence Medical Research Center, Spokane

37404-2743

Southeast Renal Research Institute, Chattanooga

Sponsors
All Listed Sponsors
lead

Goldfinch Bio, Inc.

INDUSTRY